15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis

https://doi.org/10.1016/j.jaad.2020.06.647Get rights and content

References (0)

Cited by (0)

Commercial disclosure: Bristol-Myers Squibb supported the research study and provided medical writing and printing support for this poster.

View full text